Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Cash & Current Investments (2016 - 2025)

Medifast (MED) has disclosed Cash & Current Investments for 16 consecutive years, with $61.0 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash & Current Investments changed N/A year-over-year to $61.0 million, compared with a TTM value of $133.9 million through Dec 2025, down 17.55%, and an annual FY2024 reading of $162.3 million, up 191.98% over the prior year.
  • Cash & Current Investments was $61.0 million for Q2 2025 at Medifast, down from $72.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $212.9 million in Q1 2021 and bottomed at $45.0 million in Q3 2023.
  • Average Cash & Current Investments over 5 years is $114.6 million, with a median of $113.8 million recorded in 2021.
  • The sharpest move saw Cash & Current Investments tumbled 56.4% in 2022, then soared 191.98% in 2024.
  • Year by year, Cash & Current Investments stood at $109.5 million in 2021, then dropped by 19.95% to $87.7 million in 2022, then plummeted by 36.59% to $55.6 million in 2023, then surged by 191.98% to $162.3 million in 2024, then crashed by 62.44% to $61.0 million in 2025.
  • Business Quant data shows Cash & Current Investments for MED at $61.0 million in Q2 2025, $72.9 million in Q1 2025, and $162.3 million in Q4 2024.